Thermo Fisher Scientific Inc (NYSE: TMO)’s stock price has soared by 0.56 in relation to previous closing price of 421.34. Nevertheless, the company has seen a loss of -2.53% in its stock price over the last five trading days. businesswire.com reported 2025-04-28 that WALTHAM, Mass.–(BUSINESS WIRE)–Thermo Fisher Scientific, the world leader in serving science, is employing an enhanced platform technology and a new CHO K-1 cell line that can reduce timelines to Investigational New Drug (IND) filing from 13 to nine months, helping biotech and pharmaceutical companies overcome logistical complexities within pre-clinical biologic drug development. The new CHO K-1 cell line is able to deliver up to 8g/L, providing higher protein expression levels and increased.
Is It Worth Investing in Thermo Fisher Scientific Inc (NYSE: TMO) Right Now?
Thermo Fisher Scientific Inc (NYSE: TMO) has a higher price-to-earnings ratio of 24.86x compared to its average ratio, The 36-month beta value for TMO is at 0.83. Analysts have varying views on the stock, with 18 analysts rating it as a “buy,” 8 rating it as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for TMO is 376.84M, and currently, shorts hold a 1.27% of that float. The average trading volume for TMO on April 29, 2025 was 2.26M shares.
TMO’s Market Performance
The stock of Thermo Fisher Scientific Inc (TMO) has seen a -2.53% decrease in the past week, with a -15.28% drop in the past month, and a -27.48% fall in the past quarter. The volatility ratio for the week is 3.94%, and the volatility levels for the past 30 days are at 4.65% for TMO. The simple moving average for the past 20 days is -3.65% for TMO’s stock, with a -23.00% simple moving average for the past 200 days.
Analysts’ Opinion of TMO
Many brokerage firms have already submitted their reports for TMO stocks, with Bernstein repeating the rating for TMO by listing it as a “Outperform.” The predicted price for TMO in the upcoming period, according to Bernstein is $630 based on the research report published on January 10, 2025 of the current year 2025.
TMO Trading at -13.32% from the 50-Day Moving Average
After a stumble in the market that brought TMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.52% of loss for the given period.
Volatility was left at 4.65%, however, over the last 30 days, the volatility rate increased by 3.94%, as shares sank -14.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.40% lower at present.
During the last 5 trading sessions, TMO fell by -2.62%, which changed the moving average for the period of 200-days by -21.99% in comparison to the 20-day moving average, which settled at $439.74. In addition, Thermo Fisher Scientific Inc saw -18.55% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TMO starting from Pettiti Gianluca, who proposed sale 300 shares at the price of $429.93 back on Apr 28 ’25. After this action, Pettiti Gianluca now owns shares of Thermo Fisher Scientific Inc, valued at $128,979 using the latest closing price.
Boxer Michael A, the SVP and General Counsel of Thermo Fisher Scientific Inc, sale 3,775 shares at $532.52 during a trade that took place back on Mar 10 ’25, which means that Boxer Michael A is holding 10,816 shares at $2,010,537 based on the most recent closing price.
Stock Fundamentals for TMO
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.42 for the gross margin
The net margin for Thermo Fisher Scientific Inc stands at 0.15. The total capital return value is set at 0.09. Equity return is now at value 13.75, with 6.65 for asset returns.
Based on Thermo Fisher Scientific Inc (TMO), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at 0.24. The debt to equity ratio resting at 0.69. The interest coverage ratio of the stock is 10.12.
Currently, EBITDA for the company is 11.54 billion with net debt to EBITDA at 2.84. When we switch over and look at the enterprise to sales, we see a ratio of 4.42. The receivables turnover for the company is 5.07for trailing twelve months and the total asset turnover is 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.77.
Conclusion
In conclusion, Thermo Fisher Scientific Inc (TMO) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
